Fact-checked by the Peptide Authority Editorial Board · Last reviewed:
Claim review
Peptide recovery stack claims — review
The recovery-stack space typically combines BPC-157, TB-500, injectable GHK-Cu, and growth-hormone secretagogues (CJC-1295, Ipamorelin). Marketed for tendon, ligament, joint, and post-injury recovery. This page covers what the actual evidence says — and why physiotherapy remains the NHS-evidence-based pathway.
Common recovery-stack claims
- “Cuts tendon recovery time in half”
- “Restores joint cartilage”
- “Repairs ligament tears non-surgically”
- “Accelerates post-surgical healing”
The honest picture
Preclinical (rodent) tissue-healing data exists for BPC-157 and TB-500. Cosmetic-grade topical GHK-Cu has reasonable skincare evidence; injectable GHK-Cu for joint or tendon use has none. GH-secretagogue effects on IGF-1 are short-term-measurable but clinical recovery-outcome benefit is not demonstrated.
NHS evidence-based recovery pathway
- Physiotherapist-led progressive loading (eccentric, isometric, heavy slow resistance).
- NSAIDs short-term where tolerated, with PPI cover if indicated.
- Corticosteroid injection only in selected cases (worsens long-term outcomes if overused).
- Sports-medicine specialist referral for confirmed structural injury.
- Surgical repair when indicated by MRI / clinical findings.
Frequently asked questions
- Do peptide recovery stacks heal injuries faster?
- There are no human RCTs of any peptide combination for tendon, ligament, or joint recovery. Preclinical (rodent) data exist for individual compounds. The leap to 'faster recovery' is marketing, not evidence.
- Why are these stacks so popular?
- Two-to-four mechanistically distinct compounds with overlapping 'healing' framing produce a memorable marketing story. Social-media testimonials add momentum. The underlying clinical evidence has not kept pace.
- Are these legal in the UK?
- None of BPC-157, TB-500, injectable GHK-Cu, CJC-1295, or Ipamorelin is a licensed UK medicine. Sale with healing claims engages UK medicines regulation.
- What is the WADA position?
- BPC-157 and TB-500 are treated as prohibited under S0 / S2. CJC-1295 and Ipamorelin are growth-hormone secretagogues, prohibited under S2. Strict liability applies to athletes.
- What is the evidence-based recovery pathway?
- Physiotherapist-led progressive loading is NHS first-line for tendon and ligament recovery. NSAIDs short-term, occasional corticosteroid injection, surgery for confirmed structural injury. None of these is bypassed by peptide stacking.